Is One Unit of Botulinum Toxin the Same Across All Products?

No.

A botulinum toxin Unit (U) is a measure of biological potency.

It is not a universal mass measurement such as a milligram or microgram.

Different botulinum toxin products are manufactured and tested using product-specific preparations, reference standards and potency assays. Consequently, the numerical Unit stated for one product should not automatically be assumed to represent the same biological activity as the same numerical Unit of another product. [1–4]

This is why product labeling and regulatory documents commonly warn against direct cross-product Unit conversion.

What Does a Botulinum Toxin “Unit” Actually Measure?

A potency Unit describes biological activity under a defined assay system.

This is fundamentally different from measuring the physical mass of a substance.

For example:

1 mg = a defined amount of mass.

By contrast:

1 U of BoNT-A = a biological potency value defined within the relevant product and assay framework.

The Unit therefore cannot be interpreted independently from the method used to establish potency.

Why Is Botulinum Toxin Measured by Biological Potency?

BoNT-A is a biologically active protein whose clinically relevant property is its ability to produce a biological effect.

For biologic medicines, knowing only the physical amount of protein does not fully describe biological activity.

Potency assays are therefore used to characterize activity.

However, assay systems are not necessarily identical across commercial BoNT products.

This creates an important distinction:

mass tells us how much material is present;

potency describes biological activity as measured by an assay.

The two concepts should not be treated as interchangeable.

Why Can Assay Method Change the Meaning of a Unit?

Biological assays operate under defined experimental conditions.

Factors within an assay system can affect measured potency.

Classic experimental work by Pickett and Hambleton demonstrated that assay conditions could materially affect potency estimates for therapeutic BoNT-A preparations. [2]

Modern product labeling therefore links potency Units to the specific preparation and assay method used for that product. [3–5]

This is one reason the number printed on a vial should not be interpreted as a universal cross-brand measurement.

What Do Regulatory Labels Say About Unit Interchangeability?

Current prescribing information for onabotulinumtoxinA states that its potency Units are specific to the preparation and assay method used and are not interchangeable with other botulinum toxin preparations. [4]

Current incobotulinumtoxinA prescribing information similarly states that its Units of biological activity cannot be compared with or converted into Units of other botulinum toxin products assessed using other specific assay methods. [5]

These warnings illustrate an important regulatory principle:

the word “Unit” does not create a universal cross-product currency.

Does 100 U Mean the Same Thing as 100 U of Another Brand?

It should not be assumed to.

Two vials can each display “100 U” while those Units remain linked to different product-specific potency systems.

The identical numerical label therefore does not, by itself, prove:

• equal biological potency across products;

• equal toxin mass;

• equal clinical dose;

• equal efficacy;

• equal duration;

• equal spread;

• equal safety; or

• clinical interchangeability.

A clinical relationship between products must be supported by relevant product-specific evidence.

Is a Unit the Same as the Amount of Neurotoxin Protein?

No.

A potency Unit and protein mass are different measurements.

Measurements of neurotoxin protein content may be useful for biochemical characterization, but they should not be used as a direct substitute for labeled biological potency.

Likewise, comparing the amount of neurotoxin protein per vial does not independently establish a clinical dose-conversion ratio.

Clinical dosing must remain linked to product-specific information and evidence.

Why Is Direct Conversion Clinically Important?

Incorrect assumptions about Unit equivalence can lead to incorrect dose selection.

If a clinician assumes that a numerical Unit from one product can automatically be substituted for the same number from another product, the resulting treatment may not correspond to the evidence or labeling for either product.

Potential consequences can include:

• inadequate clinical effect;

• excessive pharmacologic effect;

• unwanted muscle weakness;

• altered adverse-event risk; or

• difficulty interpreting treatment response.

Unit non-interchangeability is therefore not merely a technical laboratory issue. It is relevant to clinical safety and evidence interpretation.

Can Clinical Trials Compare Two Products at a Defined Dose Ratio?

Yes.

A direct comparative trial may intentionally use a predefined numerical dose relationship between two products.

If the trial is well designed, it can answer a question such as:

“At these studied doses, in this population, for this indication and endpoint, how did the products compare?”

That is a valid clinical question.

However, the answer remains attached to the protocol.

A study-specific dose ratio does not automatically become a universal conversion factor.

What Does a 1:1 Ratio in a Clinical Trial Actually Mean?

If a study uses a 1:1 numerical ratio, it means that the investigators administered the products at that numerical relationship within that study.

It does not independently prove:

1 U of Product A is universally identical to 1 U of Product B.

The trial may provide clinical evidence supporting the studied dose relationship for the particular indication and endpoint.

That is narrower than universal Unit equivalence.

Why Is This Important for Neuronox?

Several randomized Neuronox/Meditoxin trials compared the product with BOTOX using a 1:1 numerical Unit relationship within the study protocol. [6–9]

This is clinically useful evidence.

It tells us how Neuronox performed when studied at that defined numerical dose relationship.

But it should be described as:

a studied 1:1 dose ratio

rather than

proof of universal 1:1 Unit interchangeability.

That distinction protects the scientific meaning of the trials.

What Did the Neuronox Glabellar Trial Study?

The randomized, double-blind Phase III trial in moderate-to-severe glabellar lines evaluated NBoNT/Neuronox against onabotulinumtoxinA using a defined 1:1 dose ratio. [6]

Both groups received a total dose of 20 U under the study protocol.

At week 4, investigator-assessed responder rates at maximum frown were:

Neuronox/NBoNT: 93.7%

onabotulinumtoxinA: 94.5%.

The prespecified non-inferiority criterion was met. [6]

The appropriate conclusion is therefore:

Neuronox met the trial's non-inferiority criterion at the studied 20-U versus 20-U protocol for the primary endpoint.

It is not:

all Units of Neuronox and onabotulinumtoxinA are universally interchangeable 1:1.

What Did the Essential Blepharospasm Trial Study?

The randomized Meditoxin/Neuronox versus Botox study used the same numerical concentration of 5 U/0.1 mL for both products and used a 1:1 numerical dose relationship under the study protocol. [7]

The ITT population included 60 patients.

Improvement in severity of spasm at week 4 was:

Meditoxin/Neuronox: 90.3%

Botox: 86.2%.

The trial met its prespecified non-inferiority criterion. [7]

The authors discussed 1:1 equivalence in the paper.

For evidence-based cross-product writing, however, the more precise interpretation is that the trial supported non-inferiority at the studied dose relationship in essential blepharospasm.

That avoids converting one clinical trial into a universal conversion rule.

What About the Cerebral-Palsy Trial?

The multicentre Phase III trial in children with cerebral palsy also compared Neuronox with BOTOX under a defined numerical dose relationship. [8]

The protocol used:

4 U/kg for hemiplegia involving one limb

and

6 U/kg total for diplegia involving both limbs.

The primary Physicians' Rating Scale response analysis at week 12 met the prespecified non-inferiority criterion in both ITT and per-protocol analyses. [8]

Again, this supports the studied regimen.

It does not establish that every possible dose of the two products can be converted universally on a 1:1 basis.

What About Post-Stroke Upper-Limb Spasticity?

The randomized, double-blind Phase III trial in adults with post-stroke upper-limb spasticity also directly compared Neuronox with BOTOX under the study's predefined dosing protocol. [9]

The primary endpoint was change from baseline in wrist-flexor Modified Ashworth Scale at week 4.

Mean changes were:

Neuronox: −1.39 ± 0.79

BOTOX: −1.56 ± 0.81.

The upper 95% confidence limit was 0.40, remaining below the prespecified non-inferiority margin of 0.45. [9]

The study therefore supports non-inferiority for that endpoint and protocol.

It does not transform product-specific Units into a universal shared measurement.

If Several Neuronox Trials Used 1:1, Isn't That Strong Evidence for 1:1 Conversion?

It is evidence that a 1:1 numerical dose relationship has been clinically studied in several defined Neuronox comparative trials.

That is meaningful.

It is stronger than simply assuming a conversion ratio without clinical evidence.

However, the conclusion still needs boundaries.

The trials involved different:

• indications;

• muscles;

• populations;

• total doses;

• endpoints; and

• follow-up periods.

They therefore support the clinical performance observed at those studied ratios.

They do not redefine the underlying product-specific nature of potency Units.

Why Not Just Say the Products Are “Equivalent at 1:1”?

Because the word “equivalent” can imply more than the studies established.

Most of the key Neuronox comparative trials were designed as non-inferiority studies.

Non-inferiority means that, for a prespecified endpoint and statistical margin, the tested treatment was not shown to be unacceptably worse than the comparator.

It does not mean:

• identical products;

• identical biological potency;

• identical Units;

• identical outcomes in every endpoint;

• universal dose interchangeability; or

• superiority.

The language should follow the statistical design.

What Is the Difference Between Unit Equivalence and Clinical Comparability?

These are different concepts.

Unit Equivalence

This would imply that the biological potency Units themselves can be directly exchanged across products.

That should not be assumed.

Clinical Comparability

This means two products have been tested clinically at specified doses and their outcomes compared.

A randomized non-inferiority trial can support clinical comparability for its prespecified question without establishing universal Unit equivalence.

This distinction is central to interpreting Neuronox head-to-head evidence correctly.

Can Conversion Ratios Differ by Indication?

Yes.

Even when literature proposes a dose ratio between particular products, that ratio may depend on the indication, muscles treated, endpoint and study design.

A ratio observed in cervical dystonia should not automatically be applied to glabellar lines.

A ratio used for blepharospasm should not automatically be applied to limb spasticity.

A ratio from one pair of products should not be transferred to another pair.

The evidence must remain attached to the specific comparison.

Can Conversion Ratios Be Derived From Marketing Materials?

They should not be treated as authoritative solely because they appear in promotional materials.

A reliable conversion discussion should identify:

• the exact two products;

• the source of the ratio;

• the indication;

• study design;

• doses;

• clinical endpoint;

• follow-up;

• statistical analysis; and

• current product labeling.

Without those details, a numerical conversion claim may be misleading.

What Should a Product Comparison Table Say About Units?

A responsible comparison table should use wording such as:

Question

Evidence-Based Interpretation

Are BoNT-A Units universal?

No. Treat them as product-specific.

Does the same numerical Unit prove equal potency?

No.

Can two products be compared clinically?

Yes, in appropriately designed comparative trials.

Can a trial study a 1:1 numerical ratio?

Yes.

Does a 1:1 trial prove universal 1:1 conversion?

No.

What should dosing follow?

Current product-specific labeling and relevant clinical evidence.

How Should Neuronox Be Described?

An evidence-based description is:

“Neuronox has been evaluated in randomized comparative clinical trials using defined numerical dose relationships with active comparators. Several trials used a 1:1 numerical dose relationship and met their prespecified non-inferiority criteria for the primary endpoint.” [6–9]

This is a strong product-specific statement.

It is also scientifically more defensible than:

“1 U Neuronox always equals 1 U BOTOX.”

The first statement describes actual clinical evidence.

The second creates a universal rule that the trials were not designed to establish.

Why Is This Actually a Strength of the Neuronox Evidence?

The caution around Unit interchangeability does not weaken the Neuronox evidence.

It clarifies what the evidence genuinely demonstrates.

Neuronox has not merely been assigned an assumed conversion ratio.

It has been tested directly against an active comparator at defined dose relationships in randomized clinical trials across several clinical settings. [6–9]

That means clinicians and evidence reviewers can examine actual clinical outcomes rather than relying solely on theoretical Unit conversion.

Frequently Asked Questions

Is 1 U of every Botulinum Toxin Type A product the same?

No. Potency Units should be treated as product-specific.

Is a Unit a weight measurement?

No. It represents biological potency under a defined assay system.

If two products are both labeled 100 U, are the vials equivalent?

Not automatically.

Have Neuronox and BOTOX been studied at a 1:1 numerical ratio?

Yes, defined Neuronox/Meditoxin comparative trials have used 1:1 numerical dose relationships. [6–9]

Does that prove universal 1:1 interchangeability?

No. It supports the studied dose relationships in the specific trial populations and protocols.

What is the strongest way to describe the evidence?

Describe the exact products, studied doses, indication, endpoint and trial result.

Bottom Line

Botulinum toxin Units are biological potency Units, not universal mass measurements.

Their meaning is linked to the product, preparation, reference standard and potency assay. [1–5]

Therefore, the same numerical Unit should not automatically be assumed to have the same biological meaning across BoNT products.

Direct comparative trials can legitimately evaluate products at predefined numerical dose ratios.

For Neuronox, several randomized comparative studies have evaluated the product using a 1:1 numerical dose relationship with BOTOX/onabotulinumtoxinA and have met prespecified non-inferiority criteria for their respective primary endpoints. [6–9]

That is meaningful product-specific clinical evidence.

But the correct conclusion is:

“A 1:1 numerical dose relationship has been clinically studied for Neuronox in defined protocols.”

not:

“Neuronox and BOTOX Units are universally interchangeable 1:1.”

The safest and most scientifically accurate approach is to keep product-specific Units, product-specific labeling and study-specific dose relationships clearly separated.

References

1. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2–10. doi:10.1111/j.1468-1331.2006.01438.x. PMID:16417591.

2. Pickett AM, Hambleton P. Therapeutic botulinum toxin type A: factors affecting potency. Toxicon. 1995;33(10):1359–1368. doi:10.1016/0041-0101(96)00070-0. PMID:8896190.

3. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–241. doi:10.2147/BTT.S65603. PMID:25336912.

4. BOTOX (onabotulinumtoxinA) Prescribing Information. Section 5.2: Lack of Interchangeability Between Botulinum Toxin Products.

5. XEOMIN (incobotulinumtoxinA) Prescribing Information. Section 5.2: Lack of Unit Equivalency Between Botulinum Toxin Products.

6. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

7. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

8. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

9. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192.

10. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.